Although other breast cancer subtypes including ER+/PR+/HER2-, ER+/PR-/HER2-, and HER2 overexpression have been managed by targeted therapy such as endocrine therapy and anti-HER2 therapy with improved prognosis, there are no effective therapeutic ways for TNBC [2–4]. Here, PGR is linked to breast carcinoma.